James P. Dugan

Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome.

Guillermo Garcia‐Manero, Eric S. Winer, Daniel J. DeAngelo et al. · Journal of Clinical Oncology · 2022 · 41 citations

Medicine, Pharmacology, Pharmacotherapy +15

Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone

James P. Dugan, Bradley M. Haverkos, Lynda Villagomez et al. · Clinical Cancer Research · 2018 · 30 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with <i>KMT2Ar</i> or <i>NPM1</i> Alterations

Christian Récher, Jenny O’Nions, Ibrahim Aldoss et al. · Blood · 2024 · 26 citations · Full text

Medicine, Oncology, Pharmacology +11

PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia

Brett M. Stevens, Courtney L. Jones, Amanda Winters et al. · Blood · 2018 · 25 citations

Medicine, Oncology, Pharmacology +14

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS

Guillermo Garcia‐Manero, Eric S. Winer, Daniel J. DeAngelo et al. · HemaSphere · 2022 · 25 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15